Highlights Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
15,200 ^KRW	+3.47%		+1.74%	-2.94%

Mar. 14	Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.	22-12-22	CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.	22-12-22	CI
Daewon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 20, 2022, has expired with 361,402 shares, representing 1.71% for CNY 6,001.69 million.	22-12-19	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Daewon Pharmaceutical Co., Ltd. announces an Equity Buyback for 378,549 shares.	22-09-19	CI
Daewon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-09-19	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-17	CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills	21-12-29	MT
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Daewon Pharmaceutical Co., Ltd. agreed to acquire 83.5% stake in Keukdong H-Pharm Co., Ltd. for KRW 14.1 billion.	21-05-11	CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020.	20-06-29	CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020.	20-06-29	CI
Daewon Pharmaceutical Co., Ltd.’s Equity Buyback announced on March 24, 2020, has expired with 438,900 shares, representing 2.2% for KRW 5,000.3 million.	20-06-24	CI
Daewon Pharmaceutical Co., Ltd. announces an Equity Buyback for 492,611 shares.	20-03-24	CI
Daewon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	20-03-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

Highlights

Filters